853908-49-3

Basic information

• Product Name: Benzoic acid, 5-broMo-2-[(2-nitroethenyl)aMino]-
• Synonyms: Benzoic acid, 5-broMo-2-[(2-nitroethenyl)aMino]-;5-bromo-2-(2-nitrovinylamino)benzoic acid
• CAS NO: 853908-49-3
• Molecular Formula: C₉H₇BrN₂O₄
• Molecular Weight: 287.06688
• Mol File: 853908-49-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 431.7°C at 760 mmHg
• Flash Point: 214.9°C
• Appearance: /
• Density: 1.788g/cm³
• Vapor Pressure: 3.22E-08mmHg at 25°C
• Refractive Index: 1.687
• CAS DataBase Reference: Benzoic acid, 5-broMo-2-[(2-nitroethenyl)aMino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-broMo-2-[(2-nitroethenyl)aMino]-(853908-49-3)
• EPA Substance Registry System: Benzoic acid, 5-broMo-2-[(2-nitroethenyl)aMino]-(853908-49-3)

Safety Data

• Hazardous Substances Data: 853908-49-3(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 5-bromo-2-[(2-nitroethenyl)amino]- is a chemical compound that contains a benzene ring substituted with a carboxylic acid group and a bromine atom. In addition, it also has a nitroethenylamino group attached to the benzene ring. Benzoic acid, 5-bromo-2-[(2-nitroethenyl)amino]- is commonly used in the pharmaceutical and chemical industries as an intermediate for the synthesis of various other compounds. It has applications in the production of pharmaceuticals, dyes, and perfumes. The presence of the nitroethenylamino group makes this compound potentially useful as a reagent for organic synthesis. Overall, Benzoic acid, 5-bromo-2-[(2-nitroethenyl)amino]- has diverse applications and is an important building block for the synthesis of various organic compounds.

InChI:InChI=1/C9H7BrN2O4/c10-6-1-2-8(7(5-6)9(13)14)11-3-4-12(15)16/h1-5,11H,(H,13,14)

Upstream product

• 75-52-5 nitromethane 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 860439-13-0 2-nitrovinyl-hydroxylamine 
• 74189-16-5 2-amino-5-bromobenzoic acid hydrochloride 
• 74-89-5 methylamine 

Downstream Products

• 915019-51-1 2-(4-((6-bromo-3-nitroquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile 
• 915019-52-2 2-[4-(3-amino-6-bromo-quinolin-4-ylamino)-phenyl]-2-methyl-propionitrile 
• 915019-53-3 2-(4-(8-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-25-6 2-(4-(8-bromo-2-oxo-3-(m-tolylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-27-8 2-(4-(8-bromo-3-(2-methyl-5-nitrophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-30-3 2-(4-(8-bromo-3-(3-fluoro-4-methylphenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-32-5 2-(4-(8-bromo-3-(3,5-dimethylphenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-34-7 2-(4-(8-bromo-2-oxo-3-(phenylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-36-9 2-(4-(8-bromo-2-oxo-3-tosyl-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-38-1 2-(4-(8-bromo-2-oxo-3-(thiophen-2-ylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-40-5 2-(4-(8-bromo-3-(3-fluorophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-42-7 2-(4-(8-bromo-2-oxo-3-(quinolin-8-ylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-44-9 2-(4-(3-(4-acetylphenylsulfonyl)-8-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260167-46-1 2-(4-(8-bromo-2-oxo-3-(3-(trifluoromethyl)phenylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 

Relevant articles and documents

Compound serving as Hippo signal channel inhibitor

The invention provides a compound represented by a formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound disclosed by the invention has an inhibiting effecton a Hippo signal channel, and can be used for preparing a Hippo signal channel inhibitor. Meanwhile, cell proliferation can be promoted by inhibiting a Hippo signal channel, regeneration of damagedorgans is facilitated, particularly regeneration of damaged liver tissues can be promoted, and acute liver injury can be effectively repaired. Therefore, the compound provided by the invention can also be used for preparing medicines for treating various diseases related to the Hippo signal channel, such as medicines beneficial to regeneration of damaged organs, particularly medicines beneficial to regeneration of damaged liver tissues, and medicines for repairing acute liver injury. The compound can be used for medication research in the field of organ regeneration.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.